ABT-737 is a selective and potent small molecule inhibitor of protein Bcl-2, Bcl-XL, and Bcl-w. Like a BAD BH3 peptide, ABT-737 binds to and antagonizes anti-apototic Bcl-2 family proteins instead of directly activating the apoptotic process. ABT-737 binds with high affinity (ki < 1nm) to Bcl-XL, Bcl-2 and Bcl-w, but not to Bcl-B, Mcl-1 and Al protein.

ABT-737 displays a wide range of single-agent activity against cells from lymphoma, leukemia, solid tumor SCLC, and primary cells derived from patient. In animal models, ABT-737 causes tumor regression and improves survival^1-2. ABT-737 has shown synergistic anti-tumor activity when used together with vorinostat or bemicitabine^3,4.

ABT-737 is a selective and potent small molecule inhibitor of protein Bcl-2, Bcl-XL, and Bcl-w. Like a BAD BH3 peptide, ABT-737 binds to and antagonizes anti-apototic Bcl-2 family proteins instead of directly activating the apoptotic process. ABT-737 binds with high affinity (ki < 1nm) to Bcl-XL, Bcl-2 and Bcl-w, but not to Bcl-B, Mcl-1 and Al protein.

ABT-737 displays a wide range of single-agent activity against cells from lymphoma, leukemia, solid tumor SCLC, and primary cells derived from patient. In animal models, ABT-737 causes tumor regression and improves survival^1-2. ABT-737 has shown synergistic anti-tumor activity when used together with vorinostat or bemicitabine^3,4.